General Information of Drug (ID: DM7X2HK)

Drug Name
AE-08 Drug Info
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM7X2HK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tebentafusp DMUJ1WV Gastric cancer 2B72 Approved [3]
Multi-epitope peptide melanoma vaccine DMZPEHY Melanoma 2C30 Phase 3 [4]
Melanoma vaccine DMQEC6Z Melanoma 2C30 Phase 3 [5]
Multi-epitope tyrosinase/gp100 vaccine DMN68ZL Melanoma 2C30 Phase 2 [6]
Gp100:209-217(210M) peptide vaccine DM38ARE Melanoma 2C30 Phase 2 [7]
Melanoma vaccine (ALVAC) DM3HIQY Melanoma 2C30 Discontinued in Phase 2 [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanocytes lineage-specific antigen GP100 (PMEL) TT8MK59 PMEL_HUMAN Not Available [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037366)
2 Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7.
3 Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
4 Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
5 National Cancer Institute Drug Dictionary (drug id 685201).
6 ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
7 National Cancer Institute Drug Dictionary (drug id 476335).
8 Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.